NFKB1 and neoplasm: For example, as a tumor inhibitor, CYP1A2 suppressed tumorigenicity by inhibiting HGF/MET and reduced the sensitivity of sorafenib via inhibiting the NF-kB signaling (Yu et al., 2021a, 2021b).